New hope for tough blood cancers: CBX-250 trial opens
Disease control
Recruiting now
This early-stage study tests a new drug called CBX-250 in about 72 people with certain blood cancers (like acute myeloid leukemia) that have returned or not improved with standard therapy. The main goals are to check the drug's safety and find the best dose. Participants receive …
Phase: PHASE1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:47 UTC